dihexa raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Those who eat it have visions of fearful things. Magicians or those who wish to harm someone administer it in food or drink. This herb is medicinal and its seed is used as a remedy for gout, ground up and applied to the part affected." Christian Rätsch has said, "A mild dosage produces medicinal and healing effects, a moderate dosage produces aphrodisiac effects, and high dosages are used for shamanic purposes". Wade Davis, an ethnobotanist, also lists it as an essential ingredient of a zombie potion in Haitian Vodou. In Western culture, the same species (Datura stramonium) has been said to have been commonly used by witches as an ingredient for their flying ointments and was regularly included in detailed recipes of magical ointments dating back as far as the early modern period, predominately in New England and Western Europe. During the anti-witchcraft hysteria of colonial times it was considered unlucky or inappropriate to grow D. stramonium in one's garden due to its supposed reputation for aiding in incantations.
== Overdose == An overdose of modafinil can lead to a range of symptoms and complications. Psychiatric symptoms may include psychosis, mania, hallucinations, and suicidal ideation, which can occur even in individuals without a history of mental illness and may persist after discontinuation of modafinil. Neurological complications, such as seizures, tremors, dystonia (involuntary muscle contractions), and dyskinesia (uncontrolled movements), may arise from modafinil's interaction with various neurotransmitter systems. Allergic reactions such as rash, angioedema (swelling beneath the skin), anaphylaxis (a severe whole-body allergic reaction), and Stevens–Johnson syndrome (a serious skin and mucous membrane disorder) may rarely be triggered by an immunological response to modafinil or its metabolites. Cardiovascular complications like hypertension, tachycardia (rapid heart rate), chest pain, and arrhythmias may also occur because modafinil stimulates the sympathetic nervous system. In animal studies, the median lethal dose (LD50) of modafinil varies among species and depends on the route of administration. In mice and rats, the LD50 is approximately 1250 mg/kg if administered via an injection, but the oral LD50 for rats is 3400 mg/kg. The LD50 value for humans have not been established. Human clinical trials have involved total daily doses up to 1200 mg/d for 7–21 days. Acute one-time total overdoses up to 4500 mg have not been life-threatening but resulted in symptoms like agitation, insomnia, tremor, palpitations, and gastrointestinal disturbances.
=== 29 January === The SAF made further gains in Khartoum Bahri and advanced towards the El Mek Nimr Bridge, forcing the RSF out of almost the entire city except in Hillet Hamad. Renewed fighting in El Fasher killed seven people and injured 12 others. The SAF claimed that the deaths were caused by RSF shelling on the Abu Shouk camp. The SAF also claimed to have repelled an RSF attack on the city.
Sources: en.wikipedia.org
=== ADHD === Selegiline has been limitedly studied in the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. In a small randomized trial of selegiline for treatment of ADHD in children, there were improvements in attention, hyperactivity, and learning/memory performance but not in impulsivity. A small clinical randomized trial compared selegiline to methylphenidate, a first line treatment for ADHD, and reported equivalent efficacy as assessed by parent and teacher ratings. In another small randomized controlled trial of selegiline for the treatment of adult ADHD, a high dose of the medication for 6 weeks was not significantly more effective than placebo in improving symptoms. Selegiline in its transdermal patch form (brand name Emsam) has also been assessed in the treatment of ADHD in children and adolescents in a small open-label pilot study sponsored by the manufacturer in 2003. However, there was a high rate of discontinuation and development was not further pursued.
This has resulted in an egg-shaped planet, likely to be destroyed within 400 million years. 14 August The World Health Organization (WHO) declares mpox a public health emergency of international concern for the second time in two years, following the spread of the virus in African countries. Human ageing is found to progress in two accelerated bursts from the ages of 44 and 60, rather than being a gradual and linear process. 16 August – The Planetary Habitability Laboratory publishes a report concluding that the Wow! signal was likely caused by a rare astrophysical event, the sudden brightening of a cold molecular cloud triggered by a stellar emission. 22 August – The first systematic analysis of 1,500 climate policy measures from 41 countries is published. Of the policy interventions that have been tried by 2022, it identifies 63 successful ones in terms of large trend breaks. The authors find that the introduction of a right combination of measures is crucial and that price-based instruments played a key role in these policy mixes. 23 August – BNT116, the world's first mRNA lung cancer vaccine, begins a Phase I clinical trial in seven countries. 29 August – The first global analysis estimating inadequate intakes of 15 micronutrients using dietary intake data is published, suggesting over half of the global population do not consume enough iodine (68%), vitamin E (67%), calcium (66%), iron (65%), riboflavin (55%), folate (54%), and vitamin C (53%).
Ornithine is not an amino acid directly coded for by DNA; that is, it is not a proteinogenic amino acid. However, in mammalian non-hepatic tissues, the primary role of the urea cycle is often the biosynthesis of arginine. As an intermediate in metabolic pathways, ornithine is thus quite important.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.